Ranbaxy Laboratories Ltd has informed the Stock Exchange that the company has got approval from Health Canada for manufacturing and marketing of Lisinopril. The company statement said that Ranbaxy Pharmaceuticals-Canada Inc. has got approval for Ran-Lisinopril as oral medication in 5, 10 and 20 mg from Therapeutic Products Directorate (TPD), Health Canada.

Lisinopril is suggested to patients of hypertension as an initial therapy.

Paul Drake, President, Ranbaxy Pharmaceuticals-Canada Inc. said, “We are pleased to receive this approval for RAN®-Lisinopril to expand Ranbaxy’s product portfolio of accessible generic product offerings. The product formulation was developed and data assembled by RLL. RPCI’s Sales Team will be offering product to all classes of trade in all of the Canadian provinces immediately.”

Ranbaxy Pharmaceuticals-Canada Inc. (RPCI) based in Mississauga, Ontario, Canada, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL).

Ranbaxy Labs was trading strong in stock markets. The markets were weak but Ranbaxy was up by nearly 0.8 % at 12.30.

More information can be found on NSE Website http://www.nseindia.com